Skip to main content

Economic Considerations in Medical Biotechnology

  • 110k Accesses

Abstract

New products, that are often more expensive than existing treatments, are launched every year to treat various diseases. Patients, providers, and payers desire better outcomes at lower, controllable and more predictable costs. In this chapter, we demonstrate, using examples, how the value of a new product can be attributed to different factors like improved efficacy, safety and cost-saving. Then we describe the various pharmacoeconomic analyses used to identify and evaluate the value of new therapies. We discuss the various costs that are considered in these analyses (direct, indirect, intangible, and opportunity costs), and different types of analyses that are often utilized (cost of illness, cost-minimization, cost-benefit, cost-effectiveness, and cost-utility analyses) along with examples. Payers and providers may use the results of such analyses to make formulary and coverage decisions. Finally, we discuss steps taken by some states in the US to control drug pricing and reimbursement, and the potential of recently launched biosimilars to lower health care costs spent on biological products.

Keywords

  • Value
  • Pharmacoeconomics
  • Cost of illness
  • Cost-minimization analysis
  • Cost-benefit analysis
  • Cost-effectiveness analysis
  • Cost-utility analysis
  • Biosimilars

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-00710-2_11
  • Chapter length: 11 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   89.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-00710-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   119.99
Price excludes VAT (USA)
Figure 11.1

References

  • Argenta C, Ferreira MA, Sander GB, Moreira LB (2011) Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis. Value Health 14:S89–S92

    CrossRef  Google Scholar 

  • Arrieta A, Page TF, Veledar E, Nasir K (2017a) Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 12(1):e0169761

    CrossRef  Google Scholar 

  • Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017b) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol 2(12):1369–1374

    CrossRef  Google Scholar 

  • Bootman JL, Townsend JT, McGhan WF (1991) Principles of pharmacoeconomics. Harvey Whitney Books, Cincinnati

    Google Scholar 

  • Chang K, Nash D (1998) The role of pharmacoeconomic evaluations in disease management. PharmacoEconomics 14(1):11–17

    CAS  CrossRef  Google Scholar 

  • Collins AJ, Li S, Ebben J, Ma JZ, Manning W (2000) Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36(2):282–293

    CAS  CrossRef  Google Scholar 

  • Coyle D, Lee K, Laupacis A, Fergusson D (1999) Economic analysis of erythropoietin in surgery. Canadian Coordinating Office for Health Technology Assessment, Ottawa

    Google Scholar 

  • Goulart B, Ramsey S (2011) A trial-based assessment of the utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836–845

    CrossRef  Google Scholar 

  • Grauer DW, Lee J, Odom TD, Osterhaus JT, Sanchez LA (2003) Pharmacoeconomics and outcomes: applications for patient care, 2nd edn. American College of Clinical Pharmacy, Kansas City

    Google Scholar 

  • Hwang TJ, Kesselheim AS, Sarpatwari A (2017) Value-based pricing and state reform of prescription drug costs. JAMA 318(7):609–610

    CrossRef  Google Scholar 

  • Joshnson N, Nash D (eds) (1996) The role of pharmacoeconomics in outcomes management. American Hospital Publishing, Chicago

    Google Scholar 

  • Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316(7):743–753

    CAS  CrossRef  Google Scholar 

  • Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K (2017) Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318(8):748–750

    CrossRef  Google Scholar 

  • Sarpatwari A, Avorn J, Kesselheim AS (2016) State initiatives to control medication costs — can transparency legislation help? N Engl J Med 374:2301–2304

    CrossRef  Google Scholar 

  • Segel JE (2006) Cost-of-illness studies—a primer, RTI-UNC center of excellence in health promotion economics, Jan 2006. http://www.rti.org/pubs/coi_primer.pdf

    Google Scholar 

  • Szcus TD, Schneeweiss S (2003) Pharmacoeconomics and its role in the growth of the biotechnology industry. J Commer Biotechnol 10(2):111–122

    CrossRef  Google Scholar 

  • Townsend R (1987) Postmarketing drug research and development. Drug Intell Clin Pharm 21(1pt 2):134–136

    CAS  CrossRef  Google Scholar 

  • Walkom E, Robertson J, Newby D, Pillay T (2006) The role of pharmacoeconomics in formulary decision-making: considerations for hospital and managed care pharmacy and therapeutics committees. Formulary 41:374–386

    Google Scholar 

Suggested Reading

    Pharmacoeconomic Methods and Pricing Issues

    • Bonk RJ (1999) Pharmacoeconomics in perspective. Pharmaceutical Products Press, New York

      Google Scholar 

    • Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford

      Google Scholar 

    • Kolassa EM (1997) Elements of pharmaceutical pricing. Pharmaceutical Products Press, New York

      CrossRef  Google Scholar 

    Pharmacoeconomics of Biotechnology Drugs

    • Dana WJ, Farthing K (1998) The pharmacoeconomics of high-cost biotechnology products. Pharm Pract Manag Q 18(2):23–31

      CAS  PubMed  Google Scholar 

    • Hui JW, Yee GC (1998a) Pharmacoeconomics of biotechnology drugs (part 1 of 2). J Am Pharm Assoc 38(1):93–97

      Google Scholar 

    • Hui JW, Yee GC (1998) Pharmacoeconomics of biotechnology drugs (part 2 of 2). J Am Pharm Assoc 38(2):231–233

      CAS  Google Scholar 

    • Reeder CE (1995) Pharmacoeconomics and health care outcomes management: focus on biotechnology (special supplement). Am J Health Syst Pharm 52:19,S4):S1–19,S4)S28

      Google Scholar 

    Download references

    Author information

    Authors and Affiliations

    Authors

    Corresponding author

    Correspondence to Amit S. Patel .

    Editor information

    Editors and Affiliations

    Rights and permissions

    Reprints and Permissions

    Copyright information

    © 2019 Springer Nature Switzerland AG

    About this chapter

    Verify currency and authenticity via CrossMark

    Cite this chapter

    Patel, A.S., Shirur, K.P. (2019). Economic Considerations in Medical Biotechnology. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_11

    Download citation